SCOPUS 정보 검색 플랫폼

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 7, 2006, Pages 815-816

Rituximab in refractory Wegener's granulomatosis: Favorable or not? [3]

(3) Aries, Peer M a Lamprecht, Peter a Gross, Wolfgang L a

a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; RITUXIMAB;

CLINICAL FEATURE; DRUG HALF LIFE; EPISCLERITIS; GLOMERULONEPHRITIS; GRANULOMATOUS INFLAMMATION; HUMAN; IN VITRO STUDY; LETTER; LUNG HEMORRHAGE; LYMPHOMA; NONHUMAN; OPTIC NEURITIS; PRIORITY JOURNAL; SMALL VESSEL VASCULITIS; SUBGLOTTIC STENOSIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 33645286185 PISSN: 1073449X EISSN: 1073449X Source Type: Journal
DOI: None Document Type: Letter

Times cited : (11)

References (7)

1
- 31944440872
- Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial
- Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-187.
- (2006) Am J Respir Crit Care Med , vol.173 , pp. 180-187
- Keogh, K.A.¹ Ytterberg, S.R.² Fervenza, F.C.³ Carlson, K.A.⁴ Schroeder, D.R.⁵ Specks, U.⁶

2
- 33745725917
- Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations
- In press
- Aries PM, Hellmich B, Both M, Nolle B, Voswinkel J, Holl-Ulrich K, Lamprecht P, Gross WL. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis (In press)
- Ann Rheum Dis
- Aries, P.M.¹ Hellmich, B.² Both, M.³ Nolle, B.⁴ Voswinkel, J.⁵ Holl-Ulrich, K.⁶ Lamprecht, P.⁷ Gross, W.L.⁸

3
- 12544249783
- The spectrum of Wegener's granulomatosis and disease relapse
- Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005;352:330-332.
- (2005) N Engl J Med , vol.352 , pp. 330-332
- Bacon, P.A.¹

4
- 22144448927
- Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response
- Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005;34:229-232.
- (2005) Scand J Rheumatol , vol.34 , pp. 229-232
- Omdal, R.¹ Wildhagen, K.² Hansen, T.³ Gunnarsson, R.⁴ Kristoffersen, G.⁵

5
- 25444502877
- Is PR3-ANCA formation initiated in Wegeneŕs granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production
- Voswinkel J, Muller A, Lamprecht P. Is PR3-ANCA formation initiated in Wegeneŕs granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci 2005;1051:12-19.
- (2005) Ann N Y Acad Sci , vol.1051 , pp. 12-19
- Voswinkel, J.¹ Muller, A.² Lamprecht, P.³

6
- 2942635727
- Short-lived plasmablasts and longlived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice
- Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, Radbruch A, Hiepe F, Manz RA. Short-lived plasmablasts and longlived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004;199:1577-1584.
- (2004) J Exp Med , vol.199 , pp. 1577-1584
- Hoyer, B.F.¹ Moser, K.² Hauser, A.E.³ Peddinghaus, A.⁴ Voigt, C.⁵ Eilat, D.⁶ Radbruch, A.⁷ Hiepe, F.⁸ Manz, R.A.⁹

7
- 33645320899
- Multimodal therapies and optimal schedule of antibodies: Rituximab in lymphoma as an example
- Ghielmini M. Multimodal therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. Hematology (Am Soc Hematol Educ Program) 2005;321-328.
- (2005) Hematology (Am Soc Hematol Educ Program) , pp. 321-328
- Ghielmini, M.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.